Pharmaceutical and Specialty Pharmacy Service Companies
Listed below are companies associated with the mission of the Pulmonary Hypertension Association. These are for-profit companies which have interests in PH drugs, treatments and special services. These listings are not to be taken as endorsements of the companies.
PHA’s Scientific Leadership Council has authored treatment fact sheets about each of the therapies listed below.
Accredo is a full-service specialty pharmacy dedicated to pulmonary arterial hypertension care. Accredo delivers specialized pharmacy services and comprehensive therapy management through specially trained pharmacists, nurses, reimbursement specialists, licensed social workers and patient care representatives. They all work to support patients, their families and healthcare professionals. Accredo has direct access to all FDA-approved oral, infused and inhaled PAH therapies, including:
- Adcirca (tadalafil)
- Adempas (riociguat)
- Flolan (epoprostenol)
- Letairis (ambrisentan)
- Opsumit (macitentan)
- Orenitram (treprostinil)
- Remodulin (treprostinil)
- Revatio (sildenafil)
- Tracleer (bosentan)
- Tyvaso (treprostinil)
- Uptravi (selexipag)
- Veletri (epoprostenol)
- Ventavis (iloprost)
Contact Accredo for support at 866.FIGHT.PH (866-344-4874).
AllianceRx Walgreens Prime
AllianceRx Walgreens Prime provides specialized medication for complex, genetic, rare and chronic health conditions.
Bayer HealthCare is a globally operating subgroup of Bayer AG focusing on pharmaceuticals and consumer health. They are the developer of Adempas® (riociguat), an oral soluble guanylate cyclase stimulator for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) that is recurrent/persistent after surgical treatment or inoperable.
Cané Medical Technology
Cané Medical Technology manufactures a mini pump for use with Remodulin.
CVS Specialty is a full-service provider for all approved PAH therapies including Adcirca, Adempas, Flolan, Letairis, Opsumit, Orenitram, Remodulin, Revatio, Tracleer, Tyvaso, Uptravi, Veletri, Ventavis, and various generics. The CVS Specialty PAH Care Program focuses on the unique needs of individuals with PAH and carefully monitors patient care throughout the course of therapy. Our commitment to helping patients and their physicians manage complex drug therapies by delivering individualized care and multi-channel access has made us one of the leading specialty pharmacies in the country. We provide a full-range of pharmaceutical care, dispensing FDA-approved medications.
CuraScript Specialty Distribution ensures rare disease patients get the critical medication within the hours they need it. CuraScript SD’s unique service model provides customized end-to-end distribution services to hospitals, healthcare providers and authorized specialty pharmacies for products with small patient populations. CuraScript SD provides integrated solutions for safe, expedited distribution of rare and orphan specialty pharmaceuticals. CuraScript SD offers Flolan, Tyvaso, Veletri, Ventavis and more to providers throughout the United States.
For information, contact the CuraScript SD Rare Disease team at 877-900-9223. Learn more.
Fairview Specialty Pharmacy
Fairview Specialty Pharmacy provides personal medication management services for some pulmonary hypertension therapies, including Letairis (ambrisentan) and Revatio (sildenafil citrate).
Gilead Sciences is the maker of Letairis (ambrisentan). Gilead develops pharmaceuticals for a variety of life-threatening illnesses, including cardiovascular diseases.
GlaxoSmithKline are the makers of Flolan (epoprostenol).
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. is the developer of Tracleer (bosentan), an oral dual endothelin receptor antagonist. Janssen has also in-licensed Ventavis (inhaled iloprost) from Schering AG for the treatment of pulmonary arterial hypertension, an orphan indication, for the US market. Janssen’s newest product is Veletri, epoprostenol for injection that is stable at room temperature.
Lilly is the developer of Cialis (tadalafil). Tadalafil was approved for the treatment of pulmonary hypertension in May 2009. Lilly sold the rights to commercially develop tadalafil to United Therapeutics in late 2008.
Lung Biotechnology is building a strong bridge to the future with its focus on developing innovative therapies for patients with PAH and other chronic, life-threatening pulmonary diseases. Lung Biotechnology currently markets Tyvaso (treprostinil) inhalation solution and Adcirca (tadalafil), an oral medication. Visit lungbiotechnology.com, tyvaso.com and adcirca.com for more information.
Medtronic is a medical technology company that manufactures pumps for use with Remodulin.
Pfizer is the developer of Revatio (sildenafil citrate), an oral PAH treatment. An intravenous form of Revatio was approved in November 2009 for patients currently prescribed Revatio tablets but who are temporarily unable to take oral medication.
Pharmaceutical Research and Manufacturers Association (PhRMA)
Pharmaceutical Research and Manufacturers Association (PhRMA) is the leading association of research-based pharmaceutical and biotechnology companies. The Partnership for Prescription Assistance program (888-477-2669) is dedicated to assisting patients and physicians determine eligibility for available pharmaceutical support programs.
Philips Respironics is a medical equipment manufacturer specializing in sleep and respiratory equipment.
Smiths Medical is a medical equipment manufacturer that makes pumps for use with Remodulin and Flolan.
Synergen Rx Specialty Pharmacy
Synergen Rx is a URAC accredited specialty pharmacy. Their team provides expert knowledge in navigating the approval process and copay assistance options for all oral pulmonary hypertension therapies. Synergen Rx focuses on quick, quality communication and provides readily accessible staff members, including 24/7 access to a PH specialist.
Contact Synergen Rx toll free: 888-975-2191
Teva Pharmaceuticals, a generic pharmaceutical manufacturer, markets approximately 380 products. The company manufactures epoprostenol sodium for injection, along with a broad range of products in all major therapeutic categories.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. They are the makers of Orenitram (treprostinil) extended-release tablets and Remodulin (treprostinil) injection. Visit unither.com, orenitram.com and remodulin.com for more information.
PHA’s Corporate Committee
A number of the companies listed above are part of PHA’s Corporate Committee. Through this committee, the members work together toward solutions to a wide variety of issues, including raising public visibility of PH and supporting education needs of the patient and medical community. View a full list of Corporate Committee members